Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAPTER-3 prophylaxis study of oral deucrictibant in hereditary angioedema
2024-516247-62-00Phase 3Completed
- Sponsor
- Pharvaris
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Deucrictibant extended-release prophylaxis with Placebo prophylaxis (2 arms). Started Feb 2025; status: completed.
02
Drugs
deucrictibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-516247-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516247-62-00.